Historical performance in the Cancer Monitoring category.
Source: Acquire.fyi, Jan 1, 2025 - Jul 21, 2026.
Largest mergers and acquisitions by disclosed deal value.
| Acquirer | Target | Type | Value | Headline |
|---|---|---|---|---|
| Tempus AI, Inc. | Personalis, Inc. | Acquisition | $1.5B | Tempus Buys Personalis to Lock In MRD Testing |
| Tempus AI, Inc. | Personalis, Inc. | Acquisition | $1.5B | Tempus Buys Personalis to Lock In MRD Testing |
Page 1 of latest articles and deal coverage.
The $1.5 billion deal gives Tempus direct control of a fast-growing cancer monitoring asset as reimbursement and clinical adoption begin to scale.
The $1.5 billion deal gives Tempus direct control of a fast-growing cancer monitoring asset as reimbursement and clinical adoption begin to scale.